CRP-LATEX (II)X2 SEIKEN ASSAY KIT

K030545 · Denka Seiken Co., Ltd. · DCK · Jun 2, 2003 · Immunology

Device Facts

• Record ID: K030545
• Device Name: CRP-LATEX (II)X2 SEIKEN ASSAY KIT
• Applicant: Denka Seiken Co., Ltd.
• Product Code: DCK · Immunology
• Decision Date: Jun 2, 2003
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5270
• Device Class: Class 2

Intended Use

The CRP-Latex (II)X2 SEIKEN Assay kit is an in vitro diagnostic test for the quantitative determination of C-reactive protein in human serum and lithium heparin or EDTA plasma samples by immunoturbidimetry. Measurement of C-reactive protein is useful in the detection and evaluation of infection, tissue injury and inflammatory disorders.

Device Story

Latex-enhanced turbidimetric immunoassay for quantitative C-reactive protein (CRP) measurement. Input: human serum, lithium heparin plasma, or EDTA plasma. Principle: antigen in sample binds to anti-CRP antibody adsorbed to latex particles, causing agglutination. Agglutination measured as absorbance change on automated chemistry analyzer (e.g., Hitachi 917). Concentration determined via interpolation from calibration curve. Used in clinical laboratory settings by trained personnel. Output: quantitative CRP concentration. Clinical utility: aids detection/evaluation of infection, tissue injury, and inflammatory disorders.

Clinical Evidence

Bench testing only. Comparative study on 451 donor samples vs. predicate showed high correlation (r=0.999; slope 1.012; y-intercept 0.005). Precision studies (within-run and between-day) across three control levels showed CVs ranging from 1.3% to 7.0%.

Technological Characteristics

Latex-enhanced turbidimetric immunoassay. Reagents: anti-CRP antibody adsorbed to latex particles. Detection: automated chemistry analyzer (absorbance change). Sample types: serum, lithium heparin plasma, EDTA plasma. Quantitative measurement via calibration curve interpolation.

Indications for Use

Indicated for quantitative determination of C-reactive protein in human serum, lithium heparin plasma, or EDTA plasma to aid in detection and evaluation of infection, tissue injury, and inflammatory disorders.

Regulatory Classification

Identification

A C-reactive protein immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the C-reactive protein in serum and other body fluids. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues.

Predicate Devices

• N High Sensitivity CRP Assay (K991385)

Submission Summary (Full Text)

{0}------------------------------------------------

DENKA SEIKEN CO.,LTD. 3-4-2, Nihonbashi kayabacho, Chuo-ku, Tokyo, Japan 103-0025

## I. 510(k) Summary

This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510 (k) number is: K 030545

(A)(1) Submitter's name: Denka Seiken Co., Ltd.

> Submitter's address: 3-4-2, Nihonbashi kayabacho, Chuo-ku Tokyo, Japan 103-0025

Submitter's telephone number: [phone]

Mr. Toshimi Matsunaga Contact Person: Manager Regulatory & Pharmaceutical Affairs

Date Summary Prepared: February 17, 2003

(2) Trade or proprietary device name: CRP-Latex (II)X2 SEIKEN Assay Kit

Common or usual name: Latex-enhanced turbidimetric in vitro immunoassay for determination of C-reactive protein

Classification Name: C-reactive protein immunological test system Panel: Immunology Class: II

(3) Legally marketed predicate device: N High Sensitivity CRP Assay [Dade Behring Inc. ](K991385).

(4) Subject device description:

The CRP-Latex (II)X2 SEIKEN Assay Kit is a latex in vitro diagnostic immunoassay for the quantitative determination of C-reactive protein in human serum and in heparinized and EDTA-plasma. Antigen in the sample bonds to the specific anti-CRP antibody, which has been adsorbed to latex particles, and agglutinates. The agglutination is detected as an absorbance change when read on an automated chemistry analyzer (the Hitachi 917 was used for these studies), with the magnitude of the change being proportional to the quantity of CRP in the sample. The actual concentration is then determined by interpolation from a calibration curve prepared from calibrators of known concentration.

{1}------------------------------------------------

3-4-2, Nihonbashi kayabacho, Chuo-ku, Tokyo, Japan 103-0025

(5) Subject device intended use:

The CRP-Latex (II)X2 SEIKEN Assay kit is an in vitro diagnostic test for the quantitative determination of C-reactive protein in human serum and lithium heparin or EDTA plasma samples by immunoturbidimetry. Measurement of C-reactive protein is useful in the detection and evaluation of infection, tissue injury and inflammatory disorders.

(6) Performance data:

The CRP-Latex (II)X2 SEIKEN Assay and the predicate device, N High Sensitivity CRP Assay have only minor difference that do not affect the performance, safety or effectiveness of the measurement.

Comparative performance studies conducted on 451 donor samples yielded a high correlation coefficient upon comparison of the CRP-Latex (II)X2 SEIKEN and the predicate device, N High Sensitivity CRP. The correlation coefficient r = 0.999; slope = 1.012, y intercept = 0.005 (Least squares); slope = 1.053, y intercept = - 0.004 (Passing/Bablock).

Precision studies, both within run and between day studies, were performed using three levels of control material. % CV for Level 1 did not exceed 7.0%; for Level 2, % CV did not exceed 3.4%; and for Level 3, % CV did not exceed 1.3%.

These findings serve to demonstrate that the performance of the CRP-Latex (II)X2 SEIKEN Assay kit is substantially equivalent to the predicate device, N High Sensitivity CRP (Dade Behring).

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird with three overlapping profiles, suggesting a sense of community or collaboration. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird symbol, emphasizing the organization's name and national affiliation.

## DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Mr. Toshimi Matsunaga Manager Regulatory & Pharmaceutical Affairs Denka Seiken Co., Limited 1-2-2 Minamihoncho, Gosen City Niigata, Japan 959-1695

JUN - 2 2003

Re: k030545 Trade/Device Name: CRP-Latex (II)X2 SEIKEN Assay Kit Regulation Number: 21 CFR § 866.5270 Regulation Name: C-reactive protein immunological test system Regulatory Class: II Product Code: DKC Dated: April 30, 2003 Received: May 5, 2003

Dear Mr. Matsunaga:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

{3}------------------------------------------------

Page 2 -

If you desire specific information about the application of labeling requirements to your device. or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97), You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

## Denka Seiken Co., Ltd. Pre-market Notification CRP-Latex (II) SEIKEN X2 Assay Kit

## C. Indications for use of the Device

Page 1 of 1

510(k) Number): ______________________________________________________________________________________________________________________________________________________________

CRP-Latex (II)X2 SEIKEN Assay Kit Device Name:

Indications for Use:

The CRP-Latex (II)X2 SEIKEN Assay kit is an in vitro diagnostic test for the quantitative determination of C-reactive protein in human serum and lithium heparin or EDTA plasma samples by immunoturbidimetry. Measurement of C-reactive protein is useful in the detection and evaluation of infection, tissue injury and inflammatory disorders.

(Please do not write below this line-continue on another page if needed)

* * * * * # * * *

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use_X or (Per 21 CFR 801.109) (Optional Format 1-2-96)

Over-the-Counter Use

J. Prews for S.B. Bautista

of Clinical Laboratory Devices 100 00045

510(k) Number-